Currently available data suggest that manipulation of the BCL2 family (with the decrease of both MCL1 and BCL2A1) in DC, associated with a therapeutic vaccination with autologous tolerogenic DC, might represent a suitable treatment in rheumatoid arthritis and Langerhans cell histiocytosis, possibly leading to a cure. This evidence concerns the gene BCL2A1 and rheumatoid arthritis.